Category Archives: Drugs

Can coconut oil help Alzheimer’s? disease?

Posted on by

News from the web:

There are several theories on how coconut oil might work in Alzheimer’s disease, but nothing has been proven. Unfortunately, too, the studies have included very few patients: 23 in one six-week study and 20 in another. One article that I reviewed on the use of coconut oil could find no peer-reviewed clinical studies on its use in AD. The company that manufactures Axona studied 152 patients for 90 days. Although the company claimed benefit, at 90 days both those who were taking coconut oil, and those who were not, had similar testing scores.

Read all about it HERE

visit us at AlzheimerHeadlines.com

Don’t wait for the magic bullet

Posted on by

News from the web:

Alvaro Fernandez reviews the current state of research and the prevalence of biomedical solutions to Alzheimer. He continues to make the case for life long Mental Health instead of relying on “magic bullet” drugs or treatments.

Alvaro is the co-author of he SharpBrains Guide to Brain Fitness: http://www.sharpbrains.com/book/

Read all about it HERE

visit us at AlzheimerHeadlines.com

Alzheimer and osteoporosis

Posted on by

News from the web:

Drugs commonly found to help patients with Alzheimer now also turn out to help with osteoporosis. Patients taking donepezil and rivastigmine seemed to be less vulnerable to the risk of hip fractures.

Read all about it HERE

visit us at AlzheimerHeadlines.com

New Drug Trial Aims To Prevent Alzheimer’s Before It Starts

Posted on by

News from the web:

Researchers will test an experimental drug that could prevent Alzheimer’s disease in people who are genetically slated to develop Alzheimer’s disease but have yet to exhibit symptoms

As part of the National Alzheimer’s Plan, the National Institutes of Health (NIH) awarded a $16 million grant to Banner Alzheimer’s Institute in Arizona to fund the Alzheimer’s Prevention Initiative (API), which will study whether a plaque-fighting treatment can prevent the disease. The trial will take place in Medellín, Colombia as well as select sites in North America. The majority of the study participants will come from an extended family of 5,000 people living in Medellín who are considered part of the world’s largest family affected by Alzheimer’s. The New York Times reports the family members have a specific genetic mutation that causes symptoms of cognitive impairment around age 45, then full dementia around age 51.

Read all about it HERE

visit us at AlzheimerHeadlines.com

FDA Approves Amyvid for Alzheimer’s Diagnosis

Posted on by

News from the web:

Amyvid is a radiopharmaceutical developed by the Eli Lilly Company to aid in the diagnosis of Alzheimer’s disease by causing previously invisible beta amyloid plaque deposits in the brain to show up in PET scans. The FDA has recently approved Amyvid for clinical use although its use remains somewhat controversial.

Dr. Alois Alzheimer’s discovery of the physical changes in the brain in the early 1900s has caused researchers to focus on the plaque deposits he found in autopsied brains of diseased patients.  If the plaque causes the disease, discovering the plaque before a patient’s symptoms worsen could mean closing in on a cure.

Read all about it HERE

visit us at AlzheimerHeadlines.com

Alzheimers drug Amyvid raises ethical questions

Posted on by

News from the web:

Last Friday, the FDA approved Amyvid, a drug for Alzheimer’s diagnosis that was created and developed by Penn faculty Daniel Skovronsky and Hank Kung. It dyes brain deposits of amyloid plaque, which are correlated with Alzheimer’s disease.

However, the FDA has treaded cautiously, approving Amyvid only for limited uses. If brains scanned with Amyvid test negative, then the patient will be deemed Alzheimer-negative.

Cases where the Amyvid scans test positive will only signify the patient has significant levels of plaque, but will not confirm an Alzheimer’s Disease diagnosis.

Since there is no drug on the market that successfully removes amyloid plaque, Saboury said there should be no rush to market the tracer. How useful can it be for patients to know they are at risk when there is no cure or treatment?

Read all about it HERE

visit us at AlzheimerHeadlines.com